Experimental evolution of Pseudomonas aeruginosa to colistin in spatially confined microdroplets identifies evolutionary trajectories consistent with adaptation in microaerobic lung environments

• Published in: mBio 2023-12, Vol.14 (6), p.e0150623
• Main Authors: Disney-McKeethen, Saoirse, Seo, Seokju, Mehta, Heer, Ghosh, Karukriti, Shamoo, Yousif
• Format: Article
• Language: English
• Subjects: Adaptation, Physiological; Aerobiosis; Anti-Bacterial Agents - pharmacology; Antimicrobial Chemotherapy; Bacterial Proteins - genetics; Bacterial Proteins - metabolism; colistin; Colistin - pharmacology; cystic fibrosis; Cystic Fibrosis - microbiology; Drug Resistance, Bacterial; experimental evolution; Humans; Lung - microbiology; microfluidics; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - genetics; Pseudomonas Infections - drug therapy; Pseudomonas Infections - microbiology; Research Article
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mbio.01506-23

Antibiotic resistance remains one of the great challenges confronting public health in the world today. Individuals with compromised immune systems or underlying health conditions are often at an increased for bacterial infections. Patients with cystic fibrosis (CF) produce thick mucus that clogs airways and provides a very favorable environment for infection by bacteria that further decrease lung function and, ultimately, mortality. CF patients are often infected by bacteria such as early in life and experience a series of chronic infections that, over time, become increasingly difficult to treat due to increased antibiotic resistance. Colistin is a major antibiotic used to treat CF patients. Clinical and laboratory studies have identified PmrA/PmrB and PhoP/PhoQ as responsible for increased resistance to colistin. Both have been identified in CF patient lungs, but why, in some cases, is it one and not the other? In this study, we show that distinct evolutionary trajectories to colistin resistance may be favored by the microaerobic partitioning found within the damaged CF lung.